4basebio Plc Expands Manufacturing Capabilities with New Facility in Cambridge
LONDON, United Kingdom, March 31, 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, has announced a significant expansion with the leasing of an innovation hub and manufacturing facility in Cambridge, UK. This strategic move is in response to the increasing demand for research-use-only (RUO) and high-quality synthetic DNA.
The new facility, located at 31-35 Saxon Way in Bar Hill, has been leased from Peterhouse, the oldest college of the University of Cambridge, known for its strong tradition of supporting academic excellence and scientific innovation. 4basebio plans to relocate to this facility in late summer 2026, following the completion of its development.
Spanning approximately 26,500 square feet, the facility will include 7,500 square feet of specialised laboratory space. This space will feature 15 individual laboratories equipped with advanced biosafety cabinets, fume hoods, and state-of-the-art air handling systems, as well as cold storage facilities and dedicated IT infrastructure. Furthermore, the design also allows for an additional 7,500 square feet for future expansion, with 2,000 square feet of laboratory space already in the planning stages.
The construction of this facility is being managed by Zero Workspace, a firm renowned for designing and delivering complex laboratory and technical environments tailored for life sciences and innovation-driven enterprises across the UK.
The ongoing demand for next-generation therapeutics is prompting biotech and pharmaceutical companies to seek high-quality synthetic DNA from reliable providers. Synthetic DNA plays a critical role in the development of mRNA vaccines and cell and gene therapies, particularly in the context of advancing personalised medicine. Compared to plasmid DNA, synthetic DNA offers several advantages including enhanced purity, safety, and scalability. As the development pipelines in these fields mature, there is a clear expectation for an increase in the demand for research and high-quality DNA manufacturing. This new facility will enable 4basebio to meet these growing needs effectively.
4basebio acknowledges the support of Seb Denby, Partner at Creative Places, for his assistance in the search for new premises, including the detailed due diligence and negotiations that secured this facility.
Dr Amy Walker, Chief Executive Officer of 4basebio, stated: “Our customers depend on us to provide high-quality synthetic DNA to support the demand for next-generation genomic therapies, including RNA therapeutics, cell and gene therapy, and vaccine development. This new facility enhances our capability to assist our customers as they progress their drug development through clinical phases. We take pride in being part of Cambridge’s world-class life sciences ecosystem, and we are committed to being the partner of choice for our collaborators.”
Barnaby Clark, Director at Zero Workspace, remarked: “We are honoured to support 4basebio in the establishment of this new facility, which will allow them to continue their pioneering work in advancing next-generation medicine. This project builds on our growing portfolio of delivering high-specification laboratory environments, enabling innovative companies to scale and enhance their cutting-edge scientific efforts.”
For more information about 4basebio and its initiatives, please visit 4basebio.com.